RESUMEN
Autosomal recessive congenital ichthyoses (ARCI) are characterized by generalized skin scaling, hyperkeratosis, erythroderma, and disabling features affecting the skin (palmoplantar keratoderma, fissures, pain, itch), eyes, ears, and joints. Disease severity and chronicity, patient disfigurement, and time and costs required for care impose a major burden on quality of life. This multicentre cross-sectional study investigated the impact of ARCI on quality of life of patients and families, using the Dermatology Life Quality Index (DLQI), the Children DLQI (CDLQI) and Family Burden of Ichthyosis (FBI) questionnaires. Disease severity was assessed by a dermatologist. A total of 94 patients were recruited, of whom 52 (55.3%) children. Mean age was 20.1 (median 13.5) years. The mean CDLQI/DLQI score was 7.8, and 21 patients scored >10, indicating a major impairment in quality of life: symptoms, feelings and treatment problems were the most affected domains of quality of life. FBI showed a major repercussion on psychological factors and work. The results of this study highlight the impact of ARCI on specific aspects of patient and family life, underlining the need for psychological support.
Asunto(s)
Eritrodermia Ictiosiforme Congénita , Ictiosis Lamelar , Ictiosis , Adulto , Niño , Estudios Transversales , Humanos , Eritrodermia Ictiosiforme Congénita/diagnóstico , Eritrodermia Ictiosiforme Congénita/epidemiología , Eritrodermia Ictiosiforme Congénita/genética , Ictiosis/diagnóstico , Ictiosis/epidemiología , Ictiosis/genética , Ictiosis Lamelar/diagnóstico , Ictiosis Lamelar/genética , Ictiosis Lamelar/terapia , Italia/epidemiología , Calidad de Vida , Adulto JovenRESUMEN
Vulvar vitiligo (VV) and vulvar lichen sclerosus (VLS), both feature skin and mucosal hypo-/depigmentation. The aim of this study was to describe the clinical and dermoscopic features of VV and VLS in the pediatric population, providing diagnostic clues, and to define their association. We performed a systematic literature review of the clinical and dermoscopic features of pediatric VV and VLS. An observational study was conducted on children affected by VLS associated with VV, referred to the Dermatology Unit of the Sant'Orsola Polyclinic in Bologna, Italy. Medical history, age at diagnosis, ethnicity, clinical and dermoscopic features, and symptoms were recorded for all patients. 124 cases of VLS and 10 cases of VV were reviewed. Clinical manifestations included hypo-/depigmented patches in both conditions, while ecchymosis/purpura and fissures/erosion were observed in VLS. Symptoms including pruritus, pain, or burning were reported only by VLS patients. In our study five patients with VLS associated with VV were retrieved. Clinical features included well-demarcated depigmented patches in VV and translucent areas, erythema, ecchymoses/purpura, and labial fusion in VLS. Dermoscopy showed white structureless areas with a whipped cream-like appearance, linear or dotted vessels, white chrysalis-like structures, erosion and red-purpuric blotches in VLS and reduced pigment network or pigment absence, intralesional spots of residual pigmentation and telangiectasias in VV. Symptoms were present in all patients. Both VV and VLS show hypo-/depigmented patches. In the presence of associated symptoms, possible VLS should be investigated with clinical and dermoscopic examination to achieve a prompt diagnosis.
Asunto(s)
Liquen Escleroso y Atrófico , Vitíligo , Liquen Escleroso Vulvar , Niño , Femenino , Humanos , Liquen Escleroso y Atrófico/complicaciones , Liquen Escleroso y Atrófico/diagnóstico , Estudios Observacionales como Asunto , Piel , Vitíligo/diagnóstico , Liquen Escleroso Vulvar/diagnósticoRESUMEN
Vascular findings have rarely been described in the setting of lichen sclerosus. Enlarged vessels within the atrophic plaques have been observed on the free margins of the labia minora and clitoral hood. The enlarged vessels completely remit upon treatment of lichen sclerosus with an ultra-potent corticosteroid ointment in the acute phase. During maintenance therapy with calcineurin inhibitors, there was no recurrence of the enlarged vessels.
Asunto(s)
Liquen Escleroso y Atrófico , Enfermedades de la Vulva , Liquen Escleroso Vulvar , Corticoesteroides , Inhibidores de la Calcineurina/uso terapéutico , Femenino , Humanos , Liquen Escleroso y Atrófico/tratamiento farmacológico , Liquen Escleroso Vulvar/tratamiento farmacológicoRESUMEN
A 9-year-old girl presented with multiple, ring-shaped, erythematous, nonscaly plaques on the trunk, face and arms, most surrounding preexisting melanocytic nevi. She had experienced recurring episodes of herpes simplex labialis over several years (average 4/year), the last occurring 10 days prior.
Asunto(s)
Eritema Multiforme , Herpes Simple , Nevo Pigmentado , Neoplasias Cutáneas , Niño , Eritema Multiforme/diagnóstico , Femenino , Herpes Simple/diagnóstico , Herpes Simple/tratamiento farmacológico , Humanos , Recurrencia Local de NeoplasiaRESUMEN
Congenital fibrous hamartoma of the tip of the tongue, a peculiar and novel entity, consists of one or two asymptomatic pearly or yellowish nodules, not exceeding 0.5 cm in maximum diameter, at the tip of the tongue, ventrally or dorsally. Unlike other localizations, congenital fibrous hamartoma of the tip of the tongue is not associated with cleft lip or palate, or with feeding problems. Surgical excision should be avoided, reserved only for dubious cases, since the lesions are benign and stable over time.
Asunto(s)
Labio Leporino , Fisura del Paladar , Hamartoma , Enfermedades de la Lengua , Hamartoma/diagnóstico , Hamartoma/cirugía , Humanos , Lengua/cirugía , Enfermedades de la Lengua/diagnóstico , Enfermedades de la Lengua/cirugíaRESUMEN
Melorheostosis (MEL) is an uncommon, sclerosing disease, characterised by hyperostosis of long bones, resembling the flowing of candle wax. The disease is sporadic and the pathogenesis is still poorly understood. Occasionally, the same family can include individuals with MEL and Osteopoikilosis (OPK), a disease characterised by multiple round foci of increased bone density. LEMD3 gene mutations are related to OPK and Buschke-Ollendorff Syndrome, a genetic condition in which an association between MEL, OPK and skin lesions is observed. In rare cases, LEMD3 mutations and recently mosaic MAP2K1 gene mutations have been correlated to MEL suggesting that somatic mosaicism could be causative of the disease. In this study, we described the clinical, radiological and molecular findings of 19 individuals with MEL and 8 with OPK and compared the results to the medical literature. The molecular analyses of this case series corroborate the available data in the medical literature, indicating that LEMD3 germline mutations are not a major cause of isolated MEL and reporting five further cases of OPK caused by LEMD3 germline mutations.
Asunto(s)
Melorreostosis/diagnóstico por imagen , Melorreostosis/genética , Osteopoiquilosis/diagnóstico por imagen , Osteopoiquilosis/genética , Adolescente , Adulto , Niño , Proteínas de Unión al ADN/genética , Femenino , Fémur/patología , Mutación de Línea Germinal , Humanos , Italia/epidemiología , MAP Quinasa Quinasa 1/genética , Masculino , Proteínas de la Membrana/genética , Persona de Mediana Edad , Mutación Puntual , Adulto JovenRESUMEN
Plaque-like myofibroblastic tumor is a rare and benign pediatric soft tissue tumor. It presents as a slowly growing plaque reaching several centimeters in diameter, made up of multiple nodules. The clinical and histological features of this benign entity are similar to other fibrohistiocytic or myofibroblastic tumors occurring in childhood, so the diagnosis can be difficult. The correlation between clinical data, histopathology, and immunohistochemistry is necessary for the correct diagnosis.
Asunto(s)
Neoplasias de Tejido Muscular , Neoplasias Cutáneas , Preescolar , Diagnóstico Diferencial , Humanos , Masculino , Neoplasias de Tejido Muscular/metabolismo , Neoplasias de Tejido Muscular/patología , Neoplasias Cutáneas/metabolismo , Neoplasias Cutáneas/patologíaAsunto(s)
COVID-19 , Dermatosis del Pie , Dermatosis de la Mano , Anomalías Cutáneas , Enfermedades de la Piel , Humanos , Pandemias , Dermatosis de la Mano/diagnóstico , Dermatosis de la Mano/etiología , Enfermedades de la Piel/diagnóstico , Dermatosis del Pie/diagnóstico , Dermatosis del Pie/epidemiologíaRESUMEN
Management of patients affected by mastocytoma (MS) includes avoiding triggering factors of mast cell degranulation, and administration of symptomatic treatment. We evaluated topical steroid treatment efficiency on the clinical course of MS in a group of patients, comparing the results with another untreated group.We retrospectively evaluated clinical data of 176 patients under 15 years of age, affected by MS and referred to our Dermatological Pediatric Service from 1996 to 2010. Ninety-one of 176 children were treated with topical steroids. Follow-up was possible in 130 of 176 patients and lasted for 56.3 months on average. We compared 62 treated and 68 untreated patients. There was not statistic difference between the two groups: (i) in the number of healed or partially improved cases; and (ii) in the time of partial regression, although it is quicker with therapy. The time of healing is 16.4 months (on average) with treatment, and 34.7 months (on average, p = 0.001) without any treatment. The resolution of MS is independent of therapy administration, but the time of healing is statistically faster using the local steroids. An appropriate treatment with them is effective and safe, considering the long time needed for spontaneous resolution.
Asunto(s)
Corticoesteroides/administración & dosificación , Mastocitoma Cutáneo/tratamiento farmacológico , Piel/efectos de los fármacos , Espera Vigilante , Administración Cutánea , Adolescente , Corticoesteroides/efectos adversos , Niño , Preescolar , Femenino , Estudios de Seguimiento , Humanos , Lactante , Recién Nacido , Masculino , Mastocitoma Cutáneo/diagnóstico , Inducción de Remisión , Estudios Retrospectivos , Piel/patología , Factores de Tiempo , Resultado del TratamientoAsunto(s)
Eritema , Perineo , Diagnóstico Diferencial , Eritema/diagnóstico , Eritema/etiología , HumanosAsunto(s)
Urticaria/diagnóstico , Urticaria/etiología , Vacunación/efectos adversos , Biomarcadores , Biopsia , Niño , Humanos , Inmunohistoquímica , Vacunas Meningococicas/administración & dosificación , Vacunas Meningococicas/efectos adversos , Vacunas Meningococicas/inmunología , Piel/patología , Vacunación/métodosRESUMEN
BACKGROUND: TNF-α inhibitors have been associated with induction of autoantibodies and autoimmune diseases. We retrospectively evaluated the incidence of autoantibodies ANA, ENA, anti-dsDNA, the occurrence of clinical symptoms and possibly related treatment failure. PATIENTS AND METHODS: The titers of ANA, ENA and anti-dsDNA were evaluated from blood samples every six months in 128 patients receiving a TNF-α inhibitor (adalimumab, etanercept, infliximab). RESULTS: Overall 37% of 128 patients treated with anti-TNF-α drug developed autoantibodies, mostly induced by infliximab; 48.48 % of patients who received infliximab presented autoantibodies. One patient developed a drug-induced lupus erythematosus. Forty-five patients were switched to one or more additional TNF-α inhibitors and 25 developed autoantibodies. CONCLUSIONS: An increased autoantibody titer is not predictive of treatment failure; particular attention to all phenomena suggestive for autoimmunity is needed in patients with a positive autoantibody titer. Further studies are needed to clarify the role of autoantibodies during anti-TNF- α therapy.
Asunto(s)
Anticuerpos Monoclonales Humanizados/efectos adversos , Anticuerpos Monoclonales Humanizados/uso terapéutico , Anticuerpos Monoclonales/efectos adversos , Anticuerpos Monoclonales/uso terapéutico , Artritis Psoriásica/tratamiento farmacológico , Artritis Psoriásica/inmunología , Autoanticuerpos/sangre , Enfermedades Autoinmunes/inducido químicamente , Inmunoglobulina G/efectos adversos , Inmunoglobulina G/uso terapéutico , Psoriasis/tratamiento farmacológico , Psoriasis/inmunología , Receptores del Factor de Necrosis Tumoral/uso terapéutico , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Adalimumab , Adulto , Anticuerpos Antinucleares/sangre , Enfermedades Autoinmunes/inmunología , ADN/inmunología , Etanercept , Femenino , Humanos , Infliximab , Lupus Eritematoso Sistémico/inducido químicamente , Lupus Eritematoso Sistémico/inmunología , Masculino , Persona de Mediana Edad , Estudios RetrospectivosRESUMEN
BACKGROUND: Since the COVID-19 pandemic started, great interest has been given to this disease, especially to its possible clinical presentations. Besides classical respiratory symptoms, dermatological manifestations occur quite often among infected and non-infected patients, particularly in children. A prominent IFN-I response, that is generally higher in children compared to adults, may not only cause chilblain lesions, but it could also prevent infection and viral replication, thus justifying the negative swab results, as well as the absence of relevant systemic symptoms in positive cases. Indeed, reports have emerged describing chilblain-like acral lesions in children and adolescents with either proven or suspected infection. METHODS: Patients aged from 1 to 18 years old were enrolled in this study from 23 Italian dermatological units and were observed for an overall period of 6 months. Clinical pictures were collected along with data on the location and duration of skin lesions, their association with concomitant local and systemic symptoms, presence of nail and/or mucosal involvement, as well as histological, laboratory and imaging findings. RESULTS: One hundred thirty-seven patients were included, of whom 56.9% were females. Mean age was 11.97±3.66 years. The most commonly affected sites were the feet (77 patients, 56.2%). Lesions (48.5%) featured cyanosis, chilblains, blisters, ecchymosis, bullae, erythema, edema, and papules. Concomitant skin manifestations included maculo-papular rashes (30%), unspecified rashes (25%), vesicular rashes (20%), erythema multiforme (10%), urticaria (10%) and erythema with desquamation (5%). Forty-one patients (29.9%) reported pruritus as the main symptom associated with chilblains, and 56 out of 137 patients also reported systemic symptoms such as respiratory symptoms (33.9%), fever (28%), intestinal (27%), headache (5.5%), asthenia (3.5%), and joint pain (2%). Associated comorbid conditions were observed in 9 patients presenting with skin lesions. Nasopharyngeal swabs turned out positive in 11 patients (8%), whereas the remainder were either negative (101, 73%) or unspecified (25, 18%). CONCLUSIONS: COVID-19 has been credited as the etiology of the recent increase in acro-ischemic lesions. The present study provides a description of pediatric cutaneous manifestations deemed to be potentially associated with COVID-19, revealing a possible association between acral cyanosis and nasopharyngeal swab positivity in children and teenagers. The identification and characterization of newly recognized patterns of skin involvement may aid physicians in diagnosing cases of asymptomatic or pauci-symptomatic COVID patients.
Asunto(s)
COVID-19 , Eritema Pernio , Exantema , Adulto , Femenino , Humanos , Adolescente , Niño , Lactante , Preescolar , Masculino , COVID-19/complicaciones , COVID-19/diagnóstico , COVID-19/epidemiología , Eritema Pernio/diagnóstico , Eritema Pernio/etiología , Eritema Pernio/epidemiología , Estudios Retrospectivos , Pandemias , SARS-CoV-2 , Eritema/complicaciones , Exantema/complicaciones , Italia/epidemiología , Vesícula/complicaciones , Cianosis/complicacionesAsunto(s)
Edema/diagnóstico , Púrpura/diagnóstico , Enfermedad Aguda , Diagnóstico Diferencial , Humanos , Lactante , Masculino , VasculitisRESUMEN
Cutaneous mastocytosis in children has an indolent course and undergoes spontaneous regression. Many triggering factors may cause mast cell degranulation and clinical manifestations. Knowledge of these factors is important for patients and their families. We report a case of exacerbation of urticaria pigmentosa due to mast cell degranulation caused by Enterobius vermicularis, which has not been reported before as a triggering factor.